$PMCB

$0.33 -$0.01 (2.45%) Close

$PMCB Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 10.7M shares outstanding

Who owns PMCB?

By type of holder

Institutions 6.7% Insiders 6.9% Everyone else 86.4%

Concentration Top 10 holders own 12.1%

Silverman Joshua 4.3% · Citadel Advisors LLC 2.6%

Institutional ownership

6.7%

-2.3 pts vs last qtr

Institutional holders

-5 vs last qtr

Net shares bought

−249.7K

by institutions in Q2 2026

New / sold out

1 / 6

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Jane Street Group, LLC +18.5K
Commonwealth Equity Services, LLC +9.9K

Biggest sellers in Q2 2026

Citadel Advisors LLC −76.2K
Geode Capital Management, LLC −71.4K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for PharmaCyte Biotech Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2022–FY2026

−46.0%

−14.29% a year

Each share's claim on the business

+85.3%

grew without buying or selling a share

Spent on buybacks vs paid in stock

$44.7M vs $1.61M

over 5 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years46% 1–3 years1% Under 1 year53%

Quarterly turnover

16.4%

of institutional shares changed hands

Top 10 managers, median time held

4.5 years

Super Investors

Investment managers reporting PMCB on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
CA Citadel Advisors LLC	283.4K	2.64%	−76.2K (−21.2%)	Q3 '25	0.0%
Shares held by quarter Peak holding359.5K (Q1'26) Change over 8 quarters+283.4K Share of the company2.640% Citadel Advisors LLC's full portfolio →
GC Geode Capital Management, LLC	124.2K	1.16%	−71.4K (−36.5%)	2021	0.0%
Shares held by quarter Peak holding195.7K (Q1'26) Change over 8 quarters−44.0K Share of the company1.160% Geode Capital Management, LLC's full portfolio →

Citadel Advisors LLC

283.4K

% of company

2.64%

Change vs last qtr

−76.2K (−21.2%)

Held since

Q3 '25

Geode Capital Management, LLC

124.2K

% of company

1.16%

Change vs last qtr

−71.4K (−36.5%)

Held since

2021

28 more super investors behind a free account

See every manager holding PharmaCyte Biotech Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting PMCB on Form N-PORT; together they hold 1.5% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$43.7K	56.8K	0.53%	0.00%	June 30, 2026
FE Fidelity Extended Market Index Fund Fidelity Concord Street Trust	$29.2K	58.2K	0.54%	0.00%	August 31, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$43.7K

% of company

0.53%

% of the fund

0.00%

As of

June 30, 2026

Fidelity Extended Market Index Fund

Fidelity Concord Street Trust

Position value

$29.2K

% of company

0.54%

% of the fund

0.00%

As of

August 31, 2026

3 more funds behind a free account

See every fund holding PharmaCyte Biotech Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
SJ Silverman Joshua Insider	466.3K	4.34%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company4.340% Silverman Joshua's insider activity →
SJ Schechter Jonathan Insider	192.5K	1.79%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company1.790% Schechter Jonathan's insider activity →

Silverman Joshua

Insider

466.3K

% of company

4.34%

Change vs last qtr

—

Held since

—

Schechter Jonathan

Insider

192.5K

% of company

1.79%

Change vs last qtr

—

Held since

—

3 more holders behind a free account

See every insider and 5%+ holder of PharmaCyte Biotech Inc.

Comments